Beta-blockers. Atenolol. Propranolol. Bisoprolol. Metoprolol. Labetalol. Carvedilol.
|
|
|
- Coral Wells
- 5 years ago
- Views:
Transcription
1 Drugs of CVS
2 Beta-blockers Atenolol. Propranolol. Bisoprolol. Metoprolol. Labetalol. Carvedilol.
3 Atenolol.cardioselective
4 Propranolol, nonselective
5 Bisoprolol, cardioselective
6 Metoprolol
7 Carvedilol, alpha and beta blocker
8 Labetalol. Alpha and beta blocker
9 Beta blockers Drug Atenolol Bisoprolol Carvedilol. Metoprolol. Labetalol Propranolol Duaration Varies 8-12 oral, 5.5 IV 6-12 Doses 50, , 5, , 12.5, 25 50, , 40, 80
10 Angiotensin converting enzyme inhibitors. Captopril. Enalapril. Lisinopril. Adverse effects: Dry cough and hyperkalemia. Angioedema rare but fatal
11 Captopril Capocard, capoten, midopril.
12 Enalapril Lapril. Angiotec. Renitec. Vasopril.
13 Lisinopril Zestril. Inopril.
14 ACE inhibitors doses Captopril 2 hr (half-life) 25, 50 Lisinopril. 24 duaration 5, 10 Enalapril. 24 duaration 5, 10, 20
15 Angiotensin receptor blockers Losartan. Valsartan. Candesartan. Mechanism of action: block the angiotensin II receptors
16 Losartan Cozaar. Lacine.
17 Valsartan Diovan. Arbiten.
18 Candesartan, Atacand. Bloopress.
19 ARBs Losartan Valsartan. Candesartan.
20 Calcium channel blockers Verapamil. Deltiazem. Amlodipine. Nicardipine. Felodipine. Nifedipine. Block calcium channels which lead to relaxation of smooth muscles (vasodilation)
21 Isoptin. Verapamil
22 Deltiazem Delzime. Teldim.
23 Amlodipine Lowvasc. Norvasc. Amlocard. Myodipine.
24 Adalat Nifedipine
25 Fendol. Felodipine
26 CCBs Verapamil. Deltiazem. Nifedipine. Felodipine. Amlodipine.
27 Direct vasodilators Hydralazine. Sodium nitroprusside. Nitroglycerin. Isosorbide dinitrate. Isosorbide mononitrate.
28 Digoxin Used to treat HF and arrythmia Mechanism of action: inhibits sodium/potassium pump and increaes intracellular sodium, decreasing calcium expulsion and increasing cardiac contractility.
29 Lidocaine. Antiarrythmic drug Belong to group one Block sodium channels in abnormal tissues more than normal tissues. Iv, IM routes 2 hours duration
30 Adenosine. Antiarrythmic drug IV only Duration: seconds.
31 Diuretics Furosemide. Mannitol. Acetazolamide. Amiloride. Spirnolactone. Hydrochlorothiazide. Indapmide.
32 Furosemide. Lasix. Loop diuretics. Cause hypokalemia
33 Mannitol. Osmotic diuretics. Used to treat increased intracranial pressure and cerebral edema
34 Acetazolamide. Carbonic anhydrase inhibitors. Used to treat glucoma.
35 Amiloride. Potassium-sparing diuretics. Inhibit sodium influx through ion channels in the cortical collecting tubule.
36 Spirnolactone. Potassium-sparing diuretics. Direct pharmacologic antagonism of mineral corticoid receptors.
37 Hydrochlorothiazide. Thiazide diuretics. Inhibit sodium and chloride resorption from distal convoluted tubule.
38 Indapamide. Thiazide-like diuretics. Inhibit sodium and chloride resorption from distal convoluted tubule.
39 Heparin. Anticoagulant. Accelerate antithrombin action. Unfractionated heparin.
40 Enoxaparin. Anticoagulant. Low molecular weight heparin. 30 mg twice daily or 40 mg once daily Given SC.
41 Tinzaparin. Anticoagulant. Low molecular weight heparin. Given SC. Given twice or once daily.
42 Lepirudine. Direct thrombin inhibitors. Given parentrally. Can be used in heparin-induced thrombocytopenia.
43 Warfarine. Anticoagulant. Inhibit synthesis of vitamin K. Prothrombin time PT. International normalized ratio INR.
44 Aspirin. Antiplatelet. Prevent thromboxin factor synthesis.
45 Clopidogrel. Antiplatelet. Irrriverable blocking the ADP receptor on platelet.
46 Abciximab. Antiplatelet. Block of platelet glycoprotein IIb/IIIa receptors.
47 Tirofiban. Antiplatelet. Block of platelet glycoprotein IIb/IIIa receptors.
48 Alteplase. Fibrinolytic agents. Tissue plasminogen activator.
49 Streptokinase. Fibrinolytic drugs. Catalyzes the conversion of inactive plasminogen to active plasmin.
50 Aminocaproic acid. Chemically similar to amino acid lysine. Synthetic inhibitor of fibrinolysis. Competitively inhibits plasminogen activation. Orally. 6 g four times daily. Also administered IV. Adjunctive therapy in hemophilia.
51 Tranexemic acid. Analog to aminocaproic acid.
52 Antilipimic drugs Simvastatin. Rosuvastatin. Atorvastatin. Gemfibrozil. Ezetimibe.
53 Statins HMG-CoA reductase inhibitors. Simvastatins:
54 Fibric acid derivatives. Gemfibrozil.
55 Ezitimibe. Cholesterol absorption inhibitor
Chapter 2 ~ Cardiovascular system
Chapter 2 ~ Cardiovascular System: General Section 1 of 6 Chapter 2 ~ Cardiovascular system 2.1 Positive inotropic drugs 2.1.1 Cardiac glycosides DIGOXIN 2.2 Diuretics Elixir 50micrograms in 1ml Injection
Chapter / Section / Drug
2 Cardiovascular System 2.1 Positive inotropic drugs Digoxin Digoxin specific antibody ( DigiFab ) 2.2 Diuretics 2.2.1 Thiazides and related diuretics Indapamide (1 st Line) Bendroflumethiazide Metolazone
Cardiac Medications At A Glance
Cardiac Medications At A Glance 1) Anticoagulants (Also known as Blood Thinners.) Dalteparin (Fragmin), Danaparoid (Orgaran) Enoxaparin (Lovenox) Heparin (various) Tinzaparin (Innohep) Warfarin (Coumadin)
ACEBUTOLOL HCL 100MG TABLET GENERIC BETA BLOCKERS ALISKIREN 150MG TABLET RASILAZ RENIN INHIBITOR
S/N ME OF MEDICATIONS BRANDED/GENERIC DRUG CLASS * UNIT PRICE RANGE (SGD$) 1 ACEBUTOLOL HCL 100MG CAPSULE SECTRAL BETA BLOCKERS 0.50 2 ACEBUTOLOL HCL 100MG TABLET GENERIC BETA BLOCKERS 0.33 3 ALISKIREN
Heart Failure Clinician Guide JANUARY 2018
Kaiser Permanente National CLINICAL PRACTICE GUIDELINES Heart Failure Clinician Guide JANUARY 2018 Introduction This evidence-based guideline summary is based on the 2018 National Heart Failure Guideline.
Chapter 10 Worksheet Blood Pressure and Antithrombotic Agents
Complete the following. 1. A layer of cells lines each vessel in the vascular system. This layer is a passive barrier that keeps cells and proteins from going into tissues; it also contains substances
Table 1. Diuretics. Drugs Mechanisms of Action Indications Adverse Drug Effects. Table 2. Electrolyte Modifiers.
Table 1. Diuretics. hydrochlorothiazide 23 furosemide 23 triamterene 23 Inhibits sodium reabsorption at the distal convoluted tubule Inhibits sodium reabsorption at the loop of Henle Competitive inhibitor
Antihypertensive Agents Part-2. Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia
Antihypertensive Agents Part-2 Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia Agents that block production or action of angiotensin Angiotensin-converting
Information in these slides is used with permission from St. Mary s Cardiac Rehab
Information in these slides is used with permission from St. Mary s Cardiac Rehab Prescription Pointers Heart Medications Questions!! 2-4% of patients who visit ER s have experienced a medication misadventure
Heart Failure Clinician Guide JANUARY 2016
Kaiser Permanente National CLINICAL PRACTICE GUIDELINES Heart Failure Clinician Guide JANUARY 2016 Introduction This evidence-based guideline summary is based on the 2016 National Heart Failure Guideline.
5mg/5mL Liquid 25mg Tablets 50mg Tablets 100mg Tablets 50mg/5mL Suspension Special standardise strength 25mg Tablets
Chapter 2- Cardiovascular Category Drug name Strength / dose / form BCU 2.1 Positive Inotropic drugs 2.1.1 Cardiac Digoxin 62.5 microgram Tablets Glycosides 125 microgram Tablets 250 microgram Tablets
Introductory Clinical Pharmacology Chapter 41 Antihypertensive Drugs
Introductory Clinical Pharmacology Chapter 41 Antihypertensive Drugs Blood Pressure Normal = sys
Cardiovascular Risk Reduction in Diabetic Mellitus. Presenter: Dr. Martin N. Wanyoike MB.CHB., M. Med.(internal med) Physician / Cardiologist
Cardiovascular Risk Reduction in Diabetic Mellitus Presenter: Dr. Martin N. Wanyoike MB.CHB., M. Med.(internal med) Physician / Cardiologist Cardiovascular Risk Reduction in Diabetic Mellitus Disclosures
HYPERTENSION IN EMERGENCY MEDICINE Michael Jay Bresler, M.D., FACEP
HYPERTENSION IN EMERGENCY MEDICINE Michael Jay Bresler, M.D., FACEP What is normal blood pressure? Prehypertension 130-139/80-90 Compared with normal BP Double the risk for developing hypertension. Lifestyle
Chapter 2 - Cardiovascular System. Primary Care Prescribing Formulary - Preferred Drug Choices
Chapter 2 - Cardiovascular System Primary Care Prescribing Formulary - Preferred Drug Choices Drug group Drug choice Comments/notes Cardiac glycosides Thiazide diuretics Loop diuretics Aldosterone antagonist
Antihypertensive Agents
Antihypertensive Agents Southern California University of Health Sciences Physician Assistant Program Management and Treatment of Hypertension April 7, 08, presented by Ezra Levy, Pharm.D! Usual Dose,
Towards a Greater Understanding of Cardiac Medications Foundational Cardiac Concepts That Must Be Understood:
Towards a Greater Understanding of Cardiac Medications Foundational Cardiac Concepts That Must Be Understood: Cardiac Output (CO) CO=SVxHR (stroke volume x heart rate) Cardiac output: The amount of blood
REGISTRATION CRITERIA : SPECIALIST INITIATION OF TREATMENT AND FOR ANY SIGNIFICANT INCREASES IN DOSAGES OR ADDITION OF MEDICATION.
CORONARY ARTERY DISEASE REGISTRATION CRITERIA : SPECIALIST INITIATION OF TREATMENT AND FOR ANY SIGNIFICANT INCREASES IN DOSAGES OR ADDITION OF MEDICATION. * REQUEST FOR ANGIO-TENSIN RECEPTOR BLOCKER WILL
12.5mg, 25mg, 50mg. 25mg, 50mg. 2.5mg, 5mg, 10mg. 5mg, 10mg, 20mg, 100mg. 25mg. -- $2.81 Acetazolamide (IR, 125mg, 250mg, 500mg (ER)
MEDICATION COVERAGE POLICY PHARMACY AND THERAPEUTICS ADVISORY COMMITTEE POLICY: Blood Pressure P&T DATE: 5/9/2017 THERAPEUTIC CLASS: Cardiovascular Disorders REVIEW HISTORY: 9/15, 2/13, 2/08, 5/07 LOB
PHARM 504: Pharmacy Practice Winter 2009 MCP DRUGS #3: CARDIOVASCULAR PRODUCTS January 22th, 2010 Laura Knutzen
PHARM 504: Pharmacy Practice Winter 2009 MCP DRUGS #3: CARDIOVASCULAR PRODUCTS January 22th, 2010 Laura Knutzen General Tips and Information: 1. Types of Cardiovascular Disorders: Myocardial infarction
Top 200 Section 4. Cardiovascular Drugs
Top 200 Section 4 Cardiovascular Drugs Objectives After finishing this presentation the audience should be able to: Describe conditions/disease states that would make a person a candidate for drug therapy.
TREATMENT OF HYPERTENSION
TREATMENT OF HYPERTENSION Aim of treatment BP Goals Main items of treatment Lifestyle modification When to start drug Rx Pharmacological therapy 1. Relief of symptoms 2. Prevention of complications and
REGISTRATION CRITERIA : SPECIALIST INITIATION OF TREATMENT AND FOR ANY SIGNIFICANT INCREASES IN DOSAGES OR ADDITION OF MEDICATION.
CARDIOMYOPATHY REGISTRATION CRITERIA : SPECIALIST INITIATION OF TREATMENT AND FOR ANY SIGNIFICANT INCREASES IN DOSAGES OR ADDITION OF MEDICATION. * REQUEST FOR ANGIO-TENSIN RECEPTOR BLOCKER WILL REQUIRE
Antihypertensive drugs SUMMARY Made by: Lama Shatat
Antihypertensive drugs SUMMARY Made by: Lama Shatat Diuretic Thiazide diuretics The loop diuretics Potassium-sparing Diuretics *Hydrochlorothiazide *Chlorthalidone *Furosemide *Torsemide *Bumetanide Aldosterone
HypertensionTreatment Guidelines. Michaelene Urban APRN, MSN, ACNS-BC, ANP-BC
HypertensionTreatment Guidelines Michaelene Urban APRN, MSN, ACNS-BC, ANP-BC Objectives: Review the definition of the different stages of HTN. Review the current guidelines for treatment of HTN. Provided
What in the World is Functional Medicine?
What in the World is Functional Medicine? An Introduction to a Systems Based Approach of Chronic Disease Meneah R Haworth, FNP-C Disclosure v I am a student of the Institute for Functional Medicine. They
Report generated from BNF provided by FormularyComplete ( Accessed TA Number. Title Formulary Status Section
Report generated from BNF provided by FormularyComplete (www.pharmpress.com). Accessed 16 02 2017 Title Formulary Status Section TA Number TA Link Annotation ABCIXIMAB 2.9 Antiplatelet drugs This drug
CARDIAC IMAGING QUESTIONNAIRE
Date of test: / / Month day year Last name First name Middle initial Street address City State Zip code Home phone ( ) - Work phone ( ) - Cell Phone ( ) - Email: Age: Demographics: What is your ethnicity?
LESSON ASSIGNMENT. After completing this lesson you will be able to:
LESSON ASSIGNMENT SUBCOURSE MD0806 LESSON 7 Therapeutics III. Antihypertensive Agents. LESSON ASSIGNMENT Paragraphs 7-1--7-12. LESSON OBJECTIVES After completing this lesson you will be able to: 7-1. From
Select Preventive Prescription Drugs Jan. 1, 2018
Select Preventive Prescription Drugs Jan. 1, 2018 In addition to a healthy lifestyle, preventive medications can help you avoid some illnesses and conditions. Zimmer Biomet's medical options Value HSA,
Antihypertensive drugs: I. Thiazide and other diuretics:
Clinical assessment of hypertensive patient: You have to take history regarding the presence of other risk factors for CAb like diabetes mellitus, smoking, etc. Take history whether the patient takes medications
Hypertension (JNC-8)
Hypertension (JNC-8) Southern California University of Health Sciences Physician Assistant Program Management and Treatment of Hypertension April 17, 2018, presented by Ezra Levy, Pharm.D.! The 8 th Joint
Pharmacodynamics. Dr. Alia Shatanawi
Pharmacodynamics Dr. Alia Shatanawi Introduction Pharmacology is the study of the biochemical and physiological aspects of the drug effects including absorption, distribution, metabolism, elimination,
Fundamentals of Pharmacology for Veterinary Technicians Chapter 8
Figure 8-1 Figure 8-2 Figure 8-3 Figure 8-4 Figure 8-5 Figure 8-7 Figure 8-8 Figure 8-9 TABLE 8-1 Blood Flow Through the Heart The right atrium receives blood from all tissues, except the lungs, through
STANDARD treatment algorithm mmHg
STANDARD treatment algorithm 130-140mmHg (i) At BASELINE, If AVERAGE SBP 1 > 140mmHg If on no antihypertensive drugs: Start 1 drug: If >55 years old / Afro-Caribbean: Calcium channel blocker (CCB) 2 If
Hypertension is also an important risk factor in the development of chronic kidney disease and heart failure.
Hypertension Hypertension Hypertension is defined as either a sustained systolic blood pressure of greater than 140 mm Hg or a sustained diastolic blood pressure of greater than 90 mm Hg. Hypertension
perioperative management of cardiovascular drugs
perioperative management of cardiovascular drugs Dave Pappin and Vanessa Helliwell, Exeter, UK. Email: vanessahelliwell@doctors.org.uk It is estimated that by 2010 cardiovascular disease will be the leading
Section 3, Lecture 2
59-291 Section 3, Lecture 2 Diuretics: -increase in Na + excretion (naturesis) Thiazide and Related diuretics -decreased PVR due to decreases muscle contraction -an economical and effective treatment -protect
Adapted d from Federation of Health Regulatory Colleges of Ontario Template Last Updated September 18, 2017
Insert Logo or Org Name Here Primary Care Medical Directive for Hypertension Management Adapted d from Federation of Health Regulatory Colleges of Ontario Template Last Updated September 18, 2017 Title:
Management of Myocardial Infarction & Congestive Heart Failure. Dr. Dionne Dames-Rahming
Management of Myocardial Infarction & Congestive Heart Failure Dr. Dionne Dames-Rahming Myocardial Infarction Objectives of Medical Management Decrease morbidity Reduce further myocardial damage or injury
PassAssured's Pharmacy Technician Training Systems. Medication Review. Cardiovascular Drugs. Pharmacy Technician Training Systems Passassured, LLC
Medication Review Cardiovascular Drugs Pharmacy Technician Training Systems Passassured, LLC p1 Medication Review, Cardiovascular Drugs Click Here for Glossary Index! Click Here to Print Topic Help File
8/20/2018. Objectives. What is hypertension? cont. What is hypertension? Epidemiology cont. Epidemiology
Objectives Hypertension (high blood pressure): Clinical Pearls for the Pharmacy Technician Tanya Schmidt PharmD, RPh Director of Central Operations at Thrifty White Pharmacy North Dakota Board of Pharmacy
Dr Narender Goel MD (Internal Medicine and Nephrology) Financial Disclosure: None, Conflict of Interest: None
Dr Narender Goel MD (Internal Medicine and Nephrology) drnarendergoel@gmail.com Financial Disclosure: None, Conflict of Interest: None 12 th December 2013, New York Visit us at: http://kidneyscience.info/
Cardiac Drugs: Chapter 9 Worksheet Cardiac Agents. 1. drugs affect the rate of the heart and can either increase its rate or decrease its rate.
Complete the following. 1. drugs affect the rate of the heart and can either increase its rate or decrease its rate. 2. drugs affect the force of contraction and can be either positive or negative. 3.
Evaluation and Management of Acute Decompensated Heart Failure (HF) with Reduced Ejection Fraction Systolic Heart Failure (HFrEF)(EF<40%
Evaluation and Management of Acute Decompensated Heart Failure (HF) with Reduced Ejection Fraction Systolic Heart Failure (HFrEF)(EF
CARDIAC REHABILITATION PROGRAMME:- MEDICATION
CARDIAC REHABILITATION PROGRAMME:- MEDICATION AIM OF THIS SESSION Understand the reasons for taking your medications, Discuss the common side effects associated with these medications - knowing when to
Hypertension Management - Summary
Who should have blood pressure assessed? Hypertension Management - Summary All patients over the age of 40 years, every 1-3 years in order to determine their cardiovascular risk (ie. Framingham Risk Score)
Medications. Your prescriptions can be filled by your home pharmacy or by the Michigan Medicine Taubman Center outpatient pharmacy.
Medications Your prescriptions can be filled by your home pharmacy or by the Michigan Medicine Taubman Center outpatient pharmacy. What do I need to know about medications after my heart attack? When you
Heart failure. Failure? blood supply insufficient for body needs. CHF = congestive heart failure. increased blood volume, interstitial fluid
Failure? blood supply insufficient for body needs CHF = congestive heart failure increased blood volume, interstitial fluid Underlying causes/risk factors Ischemic heart disease (CAD) 70% hypertension
1/4/18. Heart Failure Guideline Review and Update. Disclosure. Pharmacist Objectives. Pharmacy Technician Objectives. What is Heart Failure?
Disclosure Heart Failure Guideline Review and Update I have had no financial relationship over the past 12 months with any commercial sponsor with a vested interest in this presentation. Natalie Beiter,
DROGAS PARA HIPERTENSION ARTERIAL JONATHAN POVEDA FERNANDEZ HSJD / 2013 FACC/FSCAI/FESC
DROGAS PARA HIPERTENSION ARTERIAL JONATHAN POVEDA FERNANDEZ HSJD / 2013 FACC/FSCAI/FESC Pharmacotherapy of HTN Rationale for reducing arterial pressure Reduce cardiac output Reduce heart rate Reduce stroke
Treatment of Essential Hypertension
2016 edition by Mark A. Simmons, PhD Department of Pharmaceutical Sciences School of Pharmacy University of Maryland Eastern Shore Originally developed by Hugh J. Burford, PhD, FCP Department of Pharmacology
Medications and your Heart. RBCH Foundation Trust
Medications and your Heart RBCH Foundation Trust Today I will try and cover Confusing cocktail of drugs? What are they for? How do I take them? What if I forget to take them? What are common side effects?
7/7/ CHD/MI LVH and LV dysfunction Dysrrhythmias Stroke PVD Renal insufficiency and failure Retinopathy. Normal <120 Prehypertension
Prevalence of Hypertension Hypertension: Diagnosis and Management T. Villela, M.D. Program Director University of California, San Francisco-San Francisco General Hospital Family and Community Medicine
Medicines for Heart Disease
Medicines for Heart Disease There are many medicines to treat heart disease. Ask your doctor, nurse, or pharmacist if you have questions about your medicines. Take medicines as directed. Do NOT stop taking
Management of Hypertension
Clinical Practice Guidelines Management of Hypertension Definition and classification of blood pressure levels (mmhg) Category Systolic Diastolic Normal
ASEBP and ARTA TARP Drugs and Reference Price by Categories
ASEBP Pantoprazole Sodium 40 mg (generic) $0.2016 ASEBP Dexlansoprazole 30 mg Dexlansoprazole 60 mg Esomeprazole 10 mg Esomeprazole 20 mg Esomeprazole 40 mg Lansoprazole 15 mg Lansoprazole 30 mg Omeprazole
Stable Angina Treatment Strategies and Current Practices in Lahore, Pakistan: A Cross-Sectional Analysis
Ahmed et al., International Current Pharmaceutical Journal, December 2016, 6(1): 1-5 http://www.icpjonline.com/documents/vol6issue1/01.pdf International Current Pharmaceutical Journal ORIGINAL RESEARCH
Hypertension (HTN) Lecture Note
Hypertension (HTN) Lecture Note October, 2009 Chuang-Ye Hong, MD, PhD, FACP Wan-Fang Hospital Taipei Medical University Outline Definition Epidemiology Measurement of BP Secondary cause Target organ damage
sympatholytics sympatholytics sympatholytics
sympatholytics sympatholytics sympatholytics CNS-ACTING SYMPATHOPLEGICS Sympathetic brain signals Doesn t affect baroreceptor reflex (no orthostatic hypotension) Methyldopa α-methylne crosses BBB (+) α-adrenoreceptors
4/3/2014 OBJECTIVES BLOOD PRESSURE BASICS. Discuss the new blood pressure guidelines (JNC 8) and recognize the changes from JNC 7
1 OBJECTIVES Discuss the new blood pressure guidelines (JNC 8) and recognize the changes from JNC 7 Review mechanisms for the main drug classes used to treat hypertension Describe the dosing strategies
ANTIHYPERTENSIVES. Assoc. Prof. Bilgen Başgut
ANTIHYPERTENSIVES Assoc. Prof. Bilgen Başgut Hypertension Hypertension is a condition in which the blood pressure is persistently higher than normal Hypertension > 140 mmhg > 90 mmhg Systolic Blood Pressure
Factors Involved in Poor Control of Risk Factors
Factors Involved in Poor Control of Risk Factors Patient compliance Clinical inertia Health Care System structure 14781 M Limitations of Formal Studies Selection of patients Recruitment and follow-up alter
Cardiovascular drugs
chapter 13 Cardiovascular drugs Cardiovascular drugs act on the heart or blood vessels to control the cardiovascular system. They are used to treat a variety of conditions from hypertension to chronic
Module 7: Pharmacological Management of Cardiovascular Diseases
Module 7: Pharmacological Management of Cardiovascular Diseases Module Aim This module is an introduction to the pharmacological management of cardiovascular diseases and related risk factors. In this
Antihypertensives. Antihypertensive Classes. RAAS Inhibitors. Renin-Angiotensin Cascade. Angiotensin Receptors. Approaches to Hypertension Treatment
Approaches to Hypertension Treatment Antihypertensives Inhibit Sympathetic impulses Inhibit contractility Inhibit heart rate Inhibit vasoconstriction Inhibit smooth muscle function Inhibit RAAS Inhibit
Drum Up Support. Living with Heart Failure. Doctor. Phone number. Emergency number. Target weight
Drum Up Support Regular doctor visits help drum up support in your favor! Living with Heart Failure Doctor Phone number Emergency number Target weight This material originated with the Arkansas Foundation
Module 1: Evidence-based Education for Health Care Professionals
Module 1: Evidence-based Education for Health Care Professionals Heart Failure is a HUGE Problem Prevalence Incidence Mortality Hospital Discharges Cost 1 5,300,000 660,000 284,965 1,084,000 $34.8 billion
Combining Antihypertensives in People with Diabetes
Combining ntihypertensives in People with Diabetes The majority of people with diabetes will develop hypertension and this subsequently increases the risk of microvascular and macrovascular complications.
HTN of pregnancy is serious and must be controlled, because without monitoring it can develop into pre-eclampsia and finally to eclampsia.
Sheet Pharmacology #7 1 Antihypertensive drugs of pregnancy: ببسسممم الله االرححممننن االرححيممم Usage of normal drugs of chronic HTN is controversial in pregnancy, because after few weeks or second trimester,
CARDIOVASCULAR SYSTEM / RENAL SYSTEM
CARDIOVASCULAR SYSTEM / RENAL SYSTEM Glomerulus- all small filtrates get filtered (except large proteins like albumin). NaCl is most prevalent. Diuretics work by blocking reabsorption of NaCl excreting
Difficult to Treat Hypertension
Difficult to Treat Hypertension According to Goldilocks JNC 8 Blood Pressure Goals (2014) BP Goal 60 years old and greater*- systolic < 150 and diastolic < 90. (Grade A)** BP Goal 18-59 years old* diastolic
Treatment of Essential Hypertension
2016 edition by Mark A. Simmons, PhD Department of Pharmaceutical Sciences School of Pharmacy University of Maryland Eastern Shore Originally developed by Hugh J. Burford, PhD, FCP Department of Pharmacology
Cardiovascular Clinical Practice Guideline Pilot Implementation
Cardiovascular Clinical Practice Guideline Pilot Implementation Pharmacologic Management of Chronic Heart Failure Sept 15, 2004 Angela Allerman, PharmD, BCPS DoD Pharmacoeconomic Center Promoting high
ANTIHYPERTENSIVE AGENTS AND VASODILATORS. Lecture 5
ANTIHYPERTENSIVE AGENTS AND VASODILATORS Lecture 5 Hypertension Blood pressure BP = CO x PVR n Interaction between autonomic nervous system, cardiovascular system and renal system Normal: 110/70 Prehypertension
Hemostasis and Blood Forming Organs
Hemostasis and Blood Forming Organs Subcommittee: Williams, Patricia B. (Chair) pbwillia@umich.edu McMillan, David dcmcmillan@unmc.edu Dobrydneva, Yuliya dobrydy@evms.edu DEFEROXAMINE FERROUS SULFATE ferrous
Chapter 23. Media Directory. Cardiovascular Disease (CVD) Hypertension: Classified into Three Categories
Chapter 23 Drugs for Hypertension Slide 37 Slide 41 Media Directory Nifedipine Animation Doxazosin Animation Upper Saddle River, New Jersey 07458 All rights reserved. Cardiovascular Disease (CVD) Includes
MODERN MANAGEMENT OF HYPERTENSION Where Do We Draw the Line? Disclosure. No relevant financial relationships. Blood Pressure and Risk
MODERN MANAGEMENT OF HYPERTENSION Where Do We Draw the Line? Disclosure No relevant financial relationships Robert B. Baron, MD MS Professor and Associate Dean UCSF School of Medicine baron@medicine.ucsf.edu
Heart Disease and Prevention PRESENTED BY: DOTTIE CRAIG NP- C, JANE ARCHER NP-C, KATHY DAPPER RN, NICCI FRAVEL RN
Heart Disease and Prevention PRESENTED BY: DOTTIE CRAIG NP- C, JANE ARCHER NP-C, KATHY DAPPER RN, NICCI FRAVEL RN Objectives Identify Normal Systolic and Diastolic Blood pressures Recognize common Antihypertensive
Antihypertensive Agents
Antihypertensive Agents Öner Süzer www.onersuzer.com osuzer@istanbul.edu.tr Last update: 13.11.2009 1 Süzer Farmakoloji 3. Baskı 2005 2 1 Süzer Farmakoloji 3. Baskı 2005 3 Süzer Farmakoloji 3. Baskı 2005
Chest Pain Acute Coronary Syndrome Version 4 4/10/17 This order set is designed to be used with an admission set or for a patient already admitted
Patient Name: Diagnosis: Allergies with reaction type: Chest Pain Acute Coronary Syndrome Version 4 4/10/17 This order set is designed to be used with an admission set or for a patient already admitted
COPYRIGHTED MATERIAL. Index. Ó 2009 John Wiley & Sons, Ltd
Index Figures and Tables are indicated by italic page numbers, Boxes by bold numbers. Abbreviations: ACS ¼ acute coronary syndrome; ECG ¼ electrocardiography; MI ¼ myocardial infarction; PCI ¼ percutaneous
12.5mg, 25mg, 50mg. 25mg, 50mg. 250mg, 500mg, 250mg/5ml. 2.5mg, 5mg, 10mg. 5mg, 10mg, 20mg, 100mg. 25mg
MEDICATION COVERAGE POLICY PHARMACY AND THERAPEUTICS ADVISORY COMMITTEE POLICY: Blood Pressure P&T DATE: 9/11/2018 THERAPEUTIC CLASS: Cardiovascular Disorders REVIEW HISTORY: 5/17, 9/15, 2/13, 2/08, LOB
Module 1: Evidence-based Education for Health Care Professionals
Module 1: Evidence-based Education for Health Care Professionals Heart Failure is a HUGE Problem Prevalence Incidence Mortality Hospital Discharges Cost 1 5,300,000 660,000 284,965 1,084,000 $34.8 billion
2. Cardiovascular System
1 2. Cardiovascular System 2.1 - Positive inotropic drugs 2.1.1 Cardiac glycosides Digoxin H - Digoxin specific antibody (Digifab ) Digoxin is indicated for rate control in atrial fibrillation and as add-on
NOTES: Anemia Medical condition in which the number of red blood cells (the blood count) is reduced.
Advance care planning A process in which you decide what you would like to happen to you, or not happen to you, if you become unable to make decisions about your healthcare treatment or if you are unable
Chapter 21. Diuretic Agents. Mosby items and derived items 2008, 2002 by Mosby, Inc., an affiliate of Elsevier Inc.
Chapter 21 Diuretic Agents Renal Structure and Function Kidneys at level of umbilicus Each weighs 160 to 175 g and is 10 to 12 cm long Most blood flow per gram of weight in body 22% of cardiac output (CO)
Physician/Clinic Collaborative Practice Agreement
Physician/Clinic Collaborative Practice Agreement Effective October 1, 2010, Connecticut Senate Bill 428 (PA 10-117) extends to all settings and medical conditions the opportunity for licensed pharmacists
APPENDIX D: PHARMACOTYHERAPY EVIDENCE
Página 1 de 7 APPENDIX D: PHARMACOTYHERAPY EVIDENCE Table D1. Outcome Trials of Antihypertensive Agents Study Drug Regimen N Duration Primary Outcomes Remarks Antihypertensive Therapy vs Placebo SHEP 1991
Guideline-Directed Medical Therapy
Guideline-Directed Medical Therapy Cardiovascular Outcomes Assessment of the MitraClip Percutaneous Therapy for Heart Failure Patients with Functional Mitral Regurgitation OPTIMAL THERAPY (As defined in
Antihypertensives. Diagnostic category
Measurement of blood pressure At first assessment, take both arms then choose the one with the higher reading. Beware of orthostatic hypotension. Measure BP in sitting position, and repeat after patient
Alaska Medicaid 90 Day** Generic Prescription Medication List
1 ACYCLOVIR 200 MG CAPSULE BUPROPION HCL 150 MG TAB ER 24H ACYCLOVIR 200 MG/5ML BUPROPION HCL 150 MG TABLET ER ACYCLOVIR 400 MG TABLET BUPROPION HCL 150 MG TABLET ER ACYCLOVIR 800 MG TABLET BUPROPION HCL
PRINCIPLES OF DIURETIC ACTIONS:
DIURETIC: A drug that increases excretion of solutes Increased urine volume is secondary All clinically useful diuretics act by blocking Na + reabsorption Has the highest EC to IC ratio = always more sodium
Adult Blood Pressure Clinician Guide June 2018
Kaiser Permanente National CLINICAL PRACTICE GUIDELINES Adult Blood Pressure Clinician Guide June 2018 Adult Blood Pressure Clinician Guide June 2018 Introduction This Clinician Guide is based on the 2018
Medicine Dr. Omed Lecture 2 Stable and Unstable Angina
Medicine Dr. Omed Lecture 2 Stable and Unstable Angina Risk stratification in stable angina. High Risk; *post infarct angina, *poor effort tolerance, *ischemia at low workload, *left main or three vessel
Hypertension, Hyperlipidemia and Obesity. Mi-CCSI
Hypertension, Hyperlipidemia and Obesity Mi-CCSI Objectives Review the prevalence of hypertension, hyperlipidemia and obesity Correlation of the 3 conditions Discuss why it is important to treat these
Heart Failure. Dr. William Vosik. January, 2012
Heart Failure Dr. William Vosik January, 2012 Questions for clinicians to ask Is this heart failure? What is the underlying cause? What are the associated disease processes? Which evidence-based treatment
Hypertension Update. Objectives 4/28/2015. Beverly J. Mathis, D.O. OOA May 2015
Hypertension Update Beverly J. Mathis, D.O. OOA May 2015 Objectives Learn new recommendations for BP treatment goals Approach to hypertension in the office Use of hypertensive drugs, and how to tailor
PHARMACOLOGICAL PROBLEMS
PHARMACOLOGICAL PROBLEMS 1. A 69 year old woman suffering from CHF has been treated with.25 mg Digoxin tablet daily for last 3 months. But the heart failure is not controlled adequately. What will be the